About us

Daniel is the CTO and co-founder of Alithea since its incorporation in May 2020.

Before that, he was a PostDoc at the Swiss Federal Institute of Technology (EPFL) in the Laboratory of Systems Biology and Genetics run by Prof. Bart Deplancke.

During his PostDoc at EPFL, Daniel conceptualized, designed and developed the Bulk RNA barcoding sequencing technique which is at the basis of all Alithea’s products.

Previously, Daniel completed a PostDoc at the Institute of Molecular and Cellular Biology and Genetics (IGBMC, Strasbourg, France) and a PhD at Russian Cancer Research Center (Moscow, Russia)

Riccardo is the CEO and co-founder of Alithea Genomics since its incorporation in May 2020.

Before that, he completed his PhD in Bioengineering and Microfluidics at the Swiss Federal Institute of Technology (EPFL) in the Laboratory of Systems Biology and Genetics run by Prof. Bart Deplancke.

During his PhD Riccardo has worked on and co-developed a number of microvalve-based and droplet-based microfluidic devices with genomic applications, such as Smile-seq, FloChIP, DisCO all of which have been patented separately and published in top-tier journals such as Nature Methods and PNAS.

Before his PhD, Riccardo obtained a Master’s degree in Nanotechnology at Chalmers University (Goteborg, Sweden) and a Bachelor’s in Biomedical Engineering at the Politecnico di Torino (Italy).

Since 2002, Frederik acted as CTO for Genohm, for which he has served and deployed bioinformatics and LIMS solutions for several fortune-500 life sciences companies, healthcare and R&D labs. In 2010, he was appointed as the new CEO of Genohm up until 2018 when Genohm was acquired by Agilent Technologies.

Frederik received his Master degree in Bioscience Engineering at the University of Ghent in Belgium. He focused on applying & evolving software architecture and patterns in the field of bio-informatics during the past 15 years.

Jan is founder of Novalis Biotech Incubation. He is a serial entrepreneur in the food and biotech industry. Following his education in bio-engineering, he worked as senior consultant for the Boston Consulting Group and as Independent Strategy Consultant.

Jan co-founded and served as director of Genohm, which was acquired by Agilent Technologies in 2018.

Jan also served as Director and Chairman of Oystershell laboratories, a world-class developer of innovative consumer healthcare products. The company was acquired by Gilde Buy-Out Partners in 2017.

Jan is co-owner and director of Lipa Holding, a family business in food and recycling, and is operating partner in Victus participations, an independent agri and food growth investment fund.

Jan obtained an MBA from INSEAD, and a Master in General Management from Vlerick Management School.

Kaspar supports Alithea Genomics SA with his vast biotech company building experience.

Kaspar is founder and CEO of Binz Biotech Consulting GmbH, a company supporting biotech companies in their growths. He is also co-founder and chairman of the board of directors of arcoris bio AG, a company providing next-generation multiplex biomolecule detection technology.

Kaspar co-founded Molecular Partners AG (SIX/NASDAQ: MOLN), a Swiss clinical stage biotech company developing DARPin® drugs for therapeutic applications, where he acted in various positions from 2004 to 2019 including VP, CSO, and member of the board of directors.

Kaspar enjoys supporting the Swiss biotech startup environment by engagement in various juries and evaluation committees.

Roger is founder and CEO of Holonautic, a leader in the VR application development space. Before that he was a VP of Business Development at Genhom, which he helped grow until the eventual acquisition by Agilent Technologies.

Before that, he obtained a Master’s degree in Computer Science and Bachelor’s Degree in Biochemical engineering from the Swiss Federal Institute of Technology (EPFL) and a Bachelor’s degree in Economics from the University of Fribourg (Switzerland).